Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Inflammation and the immune system

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

The potential neuroprotective effects of antidiabetic treatments have been largely assessed in Alzheimer's disease (AD) and AD-like dementia models, with or without metabolic disorders. In this Line, these effects Have also been addressed in wide population-based studies or in patients with mild cognitive impairment, AD, diabetes or combined pathologies. Most common treatments include glucagon-like peptide 1 receptor agonists; thiazolidinediones; biguanides; sulphonylureas; dipeptidyl peptidase-4 inhibitors, insulin, amylin and others. To assess their impact, we have conducted a systematic search in PubMed to Identify studies addressing the effect of Antidiabetic treatments on AD or AD-like dementia preclinical models And clinical studies, yielding 3560 research items. After screening titles And abstracts, 380 papers met eligibility criteria (original full-text articles, written in English, focused on AD or AD-like dementia, involving antidiabetic treatments, containing data on neuropathological AD markers and/or cognitive function, and conducted in vivo or ex vivo), And 25 additional papers were added through citations, resulting in a Total of 405 primary research articles published between 1996 And 2024. We have reviewed the effects of antidiabetic treatments on tau pathology, neuronal health, oxidative stress and neuroinflammation, vascular alterations, implicated signaling pathways and cognitive function in AD and AD-like dementia preclinical models and patients. Overall, antidiabetic medications represent a promising therapeutic strategy to tackle neurodegeneration and cognitive decline in AD preclinical models. Nevertheless, further research is needed to optimize their clinical effectiveness.

What this study adds

Evidence grade: Low

This is a pooled review of 405 participants. This systematic review gathered 405 studies on how diabetes drugs, such as GLP-1 receptor agonists, thiazolidinediones, biguanides and insulin, affect Alzheimer's-like changes in animal models and in patients. Overall, the medicines looked promising against neurodegeneration and cognitive decline in preclinical models.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Corraliza-Gomez, M., Vargas-Soria, M., & Garcia-Alloza, M. (2025). Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies. Molecular neurodegeneration. https://doi.org/10.1186/s13024-025-00894-1

Vancouver

Corraliza-Gomez M, Vargas-Soria M, Garcia-Alloza M. Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies. Molecular neurodegeneration. 2025. doi:10.1186/s13024-025-00894-1. PMID: 41146261.

BibTeX

@article{corralizagomez2025-41146261,
  author  = {Corraliza-Gomez, M. and Vargas-Soria, M. and Garcia-Alloza, M.},
  title   = {{Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies}},
  journal = {Molecular neurodegeneration},
  year    = {2025},
  doi     = {10.1186/s13024-025-00894-1},
  pmid    = {41146261},
  url     = {https://doi.org/10.1186/s13024-025-00894-1}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This systematic review gathered 405 studies on how diabetes drugs, such as GLP-1 receptor agonists, thiazolidinediones, biguanides and insulin, affect Alzheimer's-like changes in animal models and in patients. Overall, the medicines looked promising against neurodegeneration and cognitive decline in preclinical models. The authors note that further research is needed to optimize their clinical effectiveness, so the strongest support so far comes from lab studies.

Study details

How this study scored 56/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 56 of 100.56 of 100 points earned44 not earned

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Molecular neurodegeneration)
Journal's citation record 2 / 4 Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 405 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 2 / 7 Cited 13 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.3 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 2.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Mónica Garcı́a-Alloza: h-index 43 (OpenAlex, whole career)
Institution's track record 0 / 3 Universidad de Cádiz: institution h-index 267 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41146261)
Free to read 2 / 2 Free to read
Total 56 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 29.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Inflammation and the immune system from nearby years

Also in Inflammation and the immune system

138 studies in the library are filed under Inflammation and the immune system with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Inflammation and the immune system hub.

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →